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Abstract
Introduction: Adolescents with psychoses usually have full recovery from their first psychotic episode, but the first
relapse often arises within 2 years of the first episode. Cannabis-related psychoses are difficult to distinguish from
schizophrenic psychoses. Here, we describe a particularly severe clinical case, with a first psychotic episode occurring after
heavy cannabis smoking, an atypically long symptom-free duration, and a subsequent non-substance-related episode.
Case presentation: A 17-year-old male adolescent of Middle-East origin presented with delusions and hallucinations after
extensive cannabis smoking. His first psychotic episode, with paranoid delusions and hallucinations, progressed into
severe catatonic symptoms. His symptoms were treated with electroconvulsive therapy and risperidone and he was
transferred to a residential substance abuse treatment center. He remained drug-free and non-psychotic for 3.5 years.
Given the temporal association with extensive cannabis use, and his full remission of symptoms lasting several years, a
cannabis-induced psychosis—though atypically extended—could be suspected. However, after 3.5 years without
psychiatric care, and in a drug-free state, our patient again presented with positive psychotic symptoms, possibly induced
by a period of severe psychosocial stress.
Conclusion: We here discuss whether a primary schizophrenic episode possibly induced by cannabis can increase the risk
of subsequent non-drug-related schizophrenic episodes.
Introduction
Adolescent schizophrenia, in comparison to the adult-
onset forms, is associated with an increased family history
of schizophrenia; male predominance; more premorbid
anomalies in speech, psychomotor, and social development;
intelligence below average; insidious onset; fewer system-
atic delusions and hallucinations [1–3]; and more negative
symptoms such as flattened affects and bizarre behavior
[1]. It can present with enuresis and incontinence during
psychosis [4]. The distinction between adolescent schizo-
phrenia and other diagnoses, such as affective psychosis,
may be difficult [1]. Adolescents with schizophrenia usually
make a full recovery after the first psychotic episode, but
after 6 months of psychosis, the prognosis for full recovery
is poor [1]. The first relapse often arises within 2 years of
the end of the first episode [5–7]. Several potential predic-
tors of relapse have been discussed, including rearing
problems in the family, ethnicity, migrant status, urban up-
bringing [8], treatment discontinuation [7], social adjust-
ment, and poor adaptation to school [6].
An acute and usually transient psychosis, including a
confusional condition with delusions or hallucinations, has
been associated with prolonged cannabis intoxication
[9, 10]. Cannabis-related psychoses may be difficult to
distinguish from schizophrenic psychoses [11], but may
be partly distinguishable [12, 13] by a shorter duration
than schizophrenic episodes (typically from hours to a
few weeks) and, typically, an onset after intense canna-
bis smoking. Patients generally remain non-psychotic
in the absence of drug relapse [13, 14].
Here, we describe a severe clinical case of catatonic
schizophrenia in a male adolescent with a history of sub-
stantial cannabis smoking, and with an atypically long
period of remission between the first and second psychotic
episodes. Our aim in presenting this case is to demonstrate
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the diagnostic challenge in cannabis-induced psychosis
vis-à-vis schizophrenia, and to demonstrate the atypical
course of a patient with a psychotic disorder but with a
particularly long symptom-free period between his first
and second psychotic episodes. We also highlight the
discussion about whether cannabis might potentially
increase the risk of subsequent non-cannabis-related
psychotic episodes.
Case presentation
Six years ago, a 17-year old adolescent male of Middle-East
origin was brought to our emergency room at the Depart-
ment of Child & Adolescent Psychiatry, Malmö, Sweden,
by his mother and stepfather. Over the previous weeks,
he had reported being observed by authorities and crim-
inal gangs. He talked to himself, felt that TV broadcasts re-
ferred to his mother, and had aggressive outbursts.
Our patient lived with his mother, stepfather, and a
15-year-old brother. He had no family history of psychi-
atric disease. His psychomotor development had been
normal. After his parents’ divorce, our patient moved
from a Middle-Eastern country to Sweden with his
mother and brother. He started to use illicit drugs before
age 13. Contacts with social authorities and a regional
addiction center were established.
In our emergency room, our patient’s mother reported
that he had been smoking cannabis daily for 4 years, up
to 3g per day. For the past 2 years, he had also misused
tramadol, taking 200–1,000mg daily. He had tried lysergic
acid diethylamide, cocaine, hallucinogenic mushrooms, ec-
stasy, inhalants, and different analgesics. For the 3 weeks
preceding the emergency room visit, he had abstained
from cannabis and tramadol after being enrolled in a
youth service program related to a conviction for rob-
bery and cannabis possession. Five days prior to admission,
he still screened positive for tetrahydrocannabinol (THC).
Upon examination, our patient was mute, reacted inappro-
priately, and presented a depressed mood. A urine toxicol-
ogy test was negative for THC and other substances. After
evaluation, he returned home with a short-term prescrip-
tion of one antipsychotic medication in a very low dose
(levomepromazine, 10mg at night, for 2 consecutive days)
and alimemazine (20mg as needed, for 2 days), and with a
short-term outpatient appointment.
Six days later, still with pronounced ideas of reference,
he was voluntarily admitted to the Addiction Centre of
our hospital. A urine toxicology test was still negative.
After 4 days of inpatient care with persistent delusions,
he was transferred to the Department of Child & Adoles-
cent Psychiatry. He reported feelings of being observed by
staff and by perceived cameras in street lights, and he
laughed without obvious reason. Results from a blood
screen, computed tomography of his brain, and an electro-
encephalogram (EEG) were normal. Our patient’s delusions
and hallucinations gradually diminished. After 10 days of
inpatient care without specific psychopharmacological
treatment, he communicated almost adequately and was
discharged to a residential addiction treatment center.
One week after his arrival at the treatment institution,
our patient’s behavior was again altered. He was assessed
at the local Department of Child & Adolescent Psychiatry,
where he isolated himself, and presented bizarre body pos-
tures and inappropriate laughs. A urine toxicology test was
negative for THC and other drugs. His arm appeared to be
paralyzed and he collected saliva in his mouth. After con-
sultation with pediatric expertise, he was transferred back
to the Department of Child & Adolescent Psychiatry in his
hometown, after receiving an intramuscular injection of
10mg of olanzapine.
Upon arrival, he was mute and sat completely still, eyes
closed, with saliva running down his chin. He also pre-
sented with urine and fecal incontinence, and with asym-
metric convulsions in his arms and legs. His blood
pressure (130/60mmHg) and heart rate (80 beats per
minute) were normal. Results of an EEG and magnetic
resonance imaging (MRI) of his brain were normal. A
pediatric neurologist did not find signs of physical illness.
Possible differential diagnoses included substance-induced
psychosis, depressive stupor, catatonic schizophrenia and
neuroleptic malignant syndrome (NMS). A nasogastric
tube was introduced for nutrition. He received 20mg of di-
azepam daily. Electroconvulsive therapy (ECT) was initi-
ated along with risperidone, initially 1mg per day. During
the next 5 weeks, he received ECT 12 times with bilateral
stimulation. Risperidone was gradually increased to 3mg
per day. After the seventh ECT treatment, he opened his
eyes and started to communicate with his hands. After the
eighth ECT, the nasogastric tube was withdrawn and the
diazepam dose was reduced by half. Occasionally he talked
about the mafia, laughed inappropriately, and expressed
doubts about his medication. After the ninth ECT, the ris-
peridone dose was increased to 4mg per day, and our pa-
tient gradually improved. Colleagues from the outpatient
Psychosis Team confirmed the preliminary diagnosis of
catatonic schizophrenia. Our patient fulfilled diagnostic
criteria of catatonic schizophrenia according to the
International Classification of Diseases 10th Revision
(ICD-10 [15]), including the general schizophrenia criter-
ion (criterion A), at least four out of seven cluster B cri-
teria (criteria number 1, 3, 4, and 5), and the C criterion
excluding another factor likely to cause catatonic behav-
ior. Thus, he was diagnosed with catatonic schizophre-
nia (F20.2) and cannabis dependence (F12.2) upon
discharge from inpatient treatment, with a prompt ap-
pointment with the Psychosis Team.
During the first few weeks after discharge, our patient
relapsed into tramadol and cannabis abuse. Paranoid de-
lusions and hallucinations re-appeared, and 4 months
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after discharge he was re-hospitalized. Symptoms improved
and he was successfully discharged to another residential
addiction treatment institution.
Five years ago, having been abstinent from illicit drugs
for almost 4 months, our patient started work. The follow-
up contact with the Psychosis Team was limited to occa-
sional telephone appointments and finally ceased. Our
patient met and moved in with a girlfriend. He started for-
mal training to become a nursing assistant, and maintained
good relationships with his girlfriend and friends.
Two years ago, our patient started to feel stressed; his
girlfriend’s parents expressed doubts about his employ-
ment, and he worked and studied at the same time. He
started to be absent from classes and suffered from in-
somnia and weight loss. When his girlfriend traveled, he
became suspicious, developed delusions about being poi-
soned, and changed to vegetarian food. When his girlfriend
returned home, he was irritable and expressed ideas of ref-
erences related to TV broadcasts.
Our patient started to spend time with his mother, who
reported that he occasionally presented bizarre postures
and screamed without reason. On one occasion, he also
behaved aggressively towards his mother, and held a knife
against his own neck. He was transported by the police to
the psychiatric emergency room, where he presented with
bizarre facial expressions, inappropriate laughs, paranoid
and bizarre delusions, and aggressive and disrupted behav-
ior. Results from a urine toxicology test were negative. He
was admitted for compulsory psychiatric treatment, in-
cluding temporary physical restraint and acute intra-
muscular treatment with zuclopenthixol. Subsequently,
his medication was changed to risperidone in doses in-
creasing to 6mg per day per os. Our patient’s mother was
opposed to the medication. After two weeks of inpatient
treatment he was discharged in a somewhat improved
condition.
Owing to anxiety and sleeping problems, our patient
returned to the psychiatric emergency unit on several
occasions after discharge. He was prescribed levomeproma-
zine without significant effect. One week after discharge, he
was brought to hospital after an overdose with a prescribed
medication, reportedly levomepromazine. He denied any
suicidal intent and his urine toxicology screen was negative.
Our patient was again hospitalized for compulsory psychi-
atric treatment. He was paranoid and dysphoric. Again, his
mother was opposed to pharmacological treatment. After 5
days he was discharged with a prescription for risperidone,
25mg weekly, to be administered via the intramuscular
route by the Psychosis Team.
During the next 4 months, he was seen by a senior con-
sultant at the Psychosis Team on five occasions. Initially
he presented with a somewhat dysphoric mood, and inad-
equate smiles were reported. He was continuously op-
posed to the medication, and requested a change from
injections to oral medication. He started treatment with
risperidone, 2mg daily per os. At follow-up, 1 year ago, he
reported taking his medication and felt well.
Discussion
Differential diagnoses
Our experience with this case illustrates that adolescent
schizophrenia can be challenging to classify in individuals
with a history of smoking cannabis. The onset was acute
with delusions and hallucinations, supporting a cannabis-
related or possibly affective psychosis. Owing to the clin-
ical picture, our patient was diagnosed with schizophrenia
despite a history of heavy cannabis abuse. A catatonic sub-
type was determined given the motor immobility, extreme
negativism and mutism, and bizarre postures and facial
expressions [15]. NMS was ruled out because changes in
his level of consciousness, muscular rigidity (bizarre body
postures), and autonomic instability (urine incontin-
ence and salivation) began before therapeutic doses of
antipsychotic medication were prescribed. The absence of
leukocytosis, hyperthermia, and tachycardia along with a
normal EEG supports other diagnostic alternatives [16].
After 3.5 years of social adjustment without psychiatric
treatment, our patient’s first psychotic episode was more
likely to be classified as cannabis-induced, despite the atyp-
ically pronounced duration and severity of that first epi-
sode [13, 14]. However, after relapsing into pronounced
psychotic symptoms without any signs of substance abuse,
he was re-diagnosed with catatonic schizophrenia.
The temporal association of our patient’s first psych-
otic episode with heavy cannabis use clearly raises ques-
tions about a potential role of cannabis in psychotic
disorders. There is a relatively large amount of litera-
ture describing the association between cannabis and
acute and chronic psychosis [9–14, 17–19]. Here, the
onset of our patient’s psychosis was acute rather than
insidious, typically suggesting a cannabis-induced psych-
osis rather than schizophrenia, and although results of his
urine toxicology had returned to normal after 3 weeks of
social authority supervision, the temporal association with
heavy cannabis consumption was confirmed by our pa-
tient’s family.
The acute onset with positive symptoms, along with a
nearly full remission after 10 days of inpatient care, could
have pointed towards an affective psychosis [4]. However,
our patient presented no signs of elevated mood. Depres-
sive stupor was considered; our patient presented with de-
pressive symptoms, possibly mood-congruent delusions,
and he was clearly improved by ECT, but severe psychotic
symptoms including motor and vegetative symptoms
clearly dominated the clinical picture, and an affective
diagnosis was rejected in favor of catatonic schizophrenia
[20, 21]. Normal blood test results, an MRI of his brain,
an EEG, and consultation with pediatric expertise ruled
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out neurodegenerative psychosis. Thus, after an initial in-
terpretation of the symptoms as manifestations of a
cannabis-induced psychosis, a primary catatonic schizo-
phrenia appeared a considerably more likely explan-
ation. While an entirely substance-related etiology was
ruled out, we cannot exclude that cannabis played a signifi-
cant role in the onset of the first episode, and that it may
even have predisposed our patient to a subsequent psych-
otic episode, potentially precipitated by a stressful situation.
Although the literature is not conclusive in this area, it can-
not be ruled out that heavy cannabis abuse can be a pre-
dictor of later psychosis [18].
Proximal stressors
Our experience in this case suggests that adolescent schizo-
phrenic episodes in the same patient may potentially
be elicited by different stressors, for example, cannabis
smoking [17–19] and psychological stress [22, 23], and
cause almost the same clinical presentation. This case
illustrates the potential role of proximal risk factors for the
development of schizophrenic episodes [17–19, 22, 23].
Our patient had no known heredity predisposition for
schizophrenia, but was vulnerable in other aspects, includ-
ing stressful life events. He was brought up in a war-torn
country, his parents were divorced, and he became a
migrant with an urban up-bringing at the age of 12
years. Soon after arriving in Sweden he became socially
marginalized and failed academically. It cannot be ex-
cluded that these circumstances, together with heavy can-
nabis smoking, contributed to his illness [8, 17, 18].
Relapse prevention
An asymptomatic duration of 3.5 years of social adjust-
ment, without medication and psychiatric services, is un-
common after the first severe schizophrenic episode [5–7],
making the clinical course of the present case unusual.
Continued contact with the Psychosis Team probably
would have reduced the risk for relapse [1, 23]. The change
from a hazardous lifestyle with heavy cannabis smoking to
a drug-free state with social adaption was not enough for
our patient to maintain health. With increased social ad-
justment, our patient might have experienced a feeling of
false safety, making him end the outpatient contact
with the Psychosis Team. This case emphasizes the im-
portance of educating a patient and their parents, espe-
cially in cases where there is hesitation about treatment,
because compliance is likely to be fundamental in the
control of symptoms [1, 24]. Our patient’s mother was
critical to the pharmacological treatment, and this may
have contributed to the short treatment period and re-
hospitalization one week after discharge [25]. Pharmaco-
logical treatment is crucial for recovery [7], and more
psycho-educational efforts could have been made in
the communication with our patient and his parents,
and potentially could have improved compliance with
treatment [1]. Finally, this case demonstrates the import-
ance of maintaining at least a sparse outpatient contact
after a first psychotic episode, although this may be chal-
lenging in patients who are currently not presenting sub-
jective symptoms of disease [1, 6, 24].
Conclusions
Diagnostic classification of adolescents with psychotic symp-
toms can be challenging. Here, an assumingly cannabis-
induced psychotic episode was followed by a 3.5-year
symptom-free period in absence of drugs, but pronounced
psychotic symptoms re-appeared in the absence of drugs.
We highlight the question of whether a primary psychosis
induced by cannabis can increase the risk of subsequent
non-drug-related psychoses.
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